The present invention provides therapeutic molecules for combating sepsis. The invention provides proteins capable of improving survival through immunomodulation in post septicaemia in mammals and oligosaccharides, capable of immuno modulating inflammation in a mammal. The invention provides protein homologs of human HSP70 derived from nematode Setaria digitata and their recombinant forms and oligosaccharides and their role in immunomodulating inflammatory response in a mammal. The invention also provides a composition comprising therapeutic and/or prophylactic proteins and oligosaccharide molecules for immunomodulation in sepsis; and method for treating and/or preventing sepsis, MODS (multiple organ dysfunction syndrome) or septic shock in a mammal.

The present invention provides therapeutic molecules for combating sepsis. The invention provides proteins capable of improving survival through immunomodulation in post septicaemia in mammals and oligosaccharides, capable of immuno modulating inflammation in a mammal. The invention provides protein homologs of human HSP70 derived from nematode Setaria digitata and their recombinant forms and oligosaccharides and their role in immunomodulating inflammatory response in a mammal. The invention also provides a composition comprising therapeutic and/or prophylactic proteins and oligosaccharide molecules for immunomodulation in sepsis; and method for treating and/or preventing sepsis, MODS (multiple organ dysfunction syndrome) or septic shock in a mammal.

Scleritine is used as a protective agent for cells against toxic agents, in particular chemical or physical agents. One or more embodiments relate to a dermatological and/or cosmetic composition, which protects the skin against toxic agents, characterized in that it comprises Scleritine in at least one excipient or vehicle adapted to a topical application. One or more embodiments concerns the pharmaceutical or cosmetic industry and more specifically the formulation of pharmaceutical or cosmetic compositions intended to protect cells against toxic agents.

A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K.sup.+) channels to mediate depolarization of cellular membrane potential.

The present invention relates to a purified veterinary allergen extract enriched. In particular, the invention relates to a purified veterinary allergen extract enriched with Der f 15 and Der f 18. The invention further relates to use of the allergen extract as a veterinary product, and its use in treating allergy, in particular house dust mite allergy in mammals, more particularly, dogs.

Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as AlAT-peptide-enriched HDL particles, and their use in various therapeutic contexts.

Compositions comprising at least one major ampullate spidroin protein (MaSp)-based fiber, a polymer bound to the MaSp-based fiber, and optionally a further polymer having a molecular weight in the range of 1000 Da to 1000 kDa, are provided. Further, methods for preparation of same are provided.

Methods for treating patients having a cardiomyopathy are provided. Additionally, methods for prophylactically treating patients at risk of developing a cardiomyopathy are provided. Methods for treating patients having, or at risk of developing, a cardiomyopathy may comprise administering a fusion protein including a tafazzin peptide and a cellular permeability peptide to the patient. Further, the tafazzin peptide may be coupled to the cellular permeability peptide by a polypeptide linker.

There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutical acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

Disclosed are (i) compounds of formula I, or pharmaceutically acceptable salts thereof, and (ii) lipidoid nanoparticles comprising compound of formula I or pharmaceutically acceptable salts thereof, as well as their use as vehicles for drug delivery across the blood-brain barrier.